An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Clinical trial NCT05513001 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05513001
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-09
- Primary completion
- 2024-08-26
- Enrollment
- 696
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.